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Pharmaceutical policy not yet incorporated into
the government programme
The aims of the Second Government Programme
1
of
Prime Minister Matti Vanhanen do not include an
integral part known as the Pharmaceutical Policy.
Medicines, and not merely their costs, are neverthe-
less mentioned. The Government Agenda may also
be read and interpreted with respect to the issues
omitted.
For the last couple of decades government pro-
grammes have only superficially touched upon the
subjects of medicines and pharmacotherapy2.  If
pharmaceutical issues have been included at all in
the programmes, the aims have been set from the
standpoint of cutting the cost of medicines. This is
understandable. According to the number of pre-
scriptions, the increase in Finland in 1993–2006
reached 45%, and measured by DDD consumption
the increase was 52%. At the same time the value of
pharmaceutical sales increased by 171% and the to-
tal costs of refunds by 193 %.
The section discussing the welfare policies of the
present government also focuses when dealing with
pharmaceutical issues on the cost-cutting exercises.
It is suggested that this should be done by reforming
the drug reimbursement system. Special emphasis is
laid on the reimbursement of the cost of new drugs,
which ought to be based on their cost-effectiveness
in health care. The challenge is increased by the age-
ing of the population, especially as the aim is to
safeguard the right of the elderly population to good
care and to create a fairer payment ceiling system to
improve the situation of the big consumers of ser-
vices and medicines.
Reformed policies in the government programme
include the promoting of safe pharmacotherapies
and the safeguarding of wide-ranging pharmaceuti-
cal services. Firstly, a novelty in these political aims
is that the objective is pursued by drawing up a
clear content of issues, albeit at a rather general lev-
el. Secondly, the fact that the use of money and costs
are not tied up to the same context also presents a
novel approach. Even though the concrete content
of aims of a more general nature does not often
emerge until the government period progresses, it is
presumed that, at least, the government will not em-
bark on measures, which would jeopardise these
general aims as included in the government pro-
gramme. Safe pharmaceutical care and wide-ranging
pharmaceutical services make up good corner stone
material for any programme.
About which issues does the government pro-
gramme fall silent? Government programmes appear
to be made up of issues in need of necessary reform
at the time, about which the political parties can
then come to an agreement. No programme can in-
corporate all the issues, and, to be fair, novel issues
are constantly emerging. During this government pe-
riod we are also likely to see several pharmaceutical
issues debated in public and on the desks of the de-
cision-makers. These may include, for example, a
two-channel financing of drugs, guidelines for ratio-
nal prescribing of drugs, pharmacy fee and pharma-
cy licensing systems, sales of OTC drugs and need
for the fine tuning of the pharmaceutical administra-
tion.
The most frequently used words in the govern-
ment programme describe aims that start off with
an innovation. Immediately at the beginning of its
term the government will prepare a national innova-
tion strategy. In this context it would also be right
to evaluate the promotion of drug innovations on
national premises. Utilisation of the Finnish re-
sources of scientific know-how should be improved
in order to create innovative industrial and commer-
cial success stories. This would also support the EU
pharmaceutical sector innovation policies. 
The consumption of drugs and the importance of
pharmaceutical issues in health care will increase in
the years to come. The present government pro-
gramme refers to at least 20 different sectors of its
policies. Pharmaceutical services as a whole contains
several positive opportunities. The pharmaceutical
policy will one day have to figure in the headlines
and the programmes.
1 http://www.vn.fi/hallitus/hallitusohjelma/fi.jsp 
2 Helmiö T. et al.: Medicines in focus of the health policies.    
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Problems of pain assessment and management in
dementia patients
Pain management in patients
with dementia often raises three
problem issues: identification of
pain, choice of the most appro-
priate form of treatment and
evaluation of response. A certain
degree of sensitivity is required
for a prescriber to suspect pain
in a dementia patient as being
the causative factor of behav-
ioural changes, and new alterna-
tive methods of treatment may
actually emerge as a result.
Pain in dementia patients is
under-treated 
Several studies have proven in
unison that elderly dementia pa-
tients receive less treatment for
their pain compared with other
elderly patients suffering from
diseases afflicting them with sim-
ilar pain (1–8). The differences
are seen, for example, in cancer
(3), hip fracture (1, 4) and nurs-
ing home patients (2, 6). The dif-
ference has also been document-
ed in a Finnish survey which
states that, in comparison with
other patients, pain in nursing
home patients suffering from de-
mentia is detected and treated to
a lesser extent (7). The preva-
lence of pain in residents in
longterm care settings also ap-
pears to decrease as the severity
of the dementia increases (5). In-
dications of Alzheimer patients
receiving less treatment than pa-
tients with, for example, demen-
tia of vascular origin (8) have
provided new incentives and
prospects for studying the con-
nections between cognition and
pain.
Does the sensation of pain
change in dementia?
Changes in the sensation of pain
when ageing have been the sub-
ject of many studies and a gener-
al picture of a sort has eme-rged
despite isolated contradictory re-
search results (9–11). The periph-
eral pain threshold appears to
rise slightly as the patients are
growing older. In practice the
change is minor and it is a result
of impaired function of the A-
delta fibres in the nervous sys-
tem. The elderly also have a re-
duced tolerance of severe pain,
even though mild irritation is not
always perceived as pain as easily
by them as it is by younger pa-
tients. Impairment of pain-modu-
lating systems is thought to be
the cause. Reduced perception of
visceral pain is clinically widely
proven. Impairment of the auto-
nomic nervous system function is
presumed to be the cause here,
and may be the result of a num-
ber of diseases. It has proven dif-
ficult to ascertain the extent and
manner in which pain sensations
and reactions to pain change dur-
ing cognitive impairment (12).
According to studies by Benedett
et al., the thresholds of sensory
sensations of pain appear to be
well retained in Alzheimer’s dis-
ease, but the autonomic and af-
fective responses (medial pain
pathways) triggered by pain are
reduced (12). In this situation
even minor indications of pain-in-
duced behaviour may be a sign of
significant pain in patients with
Alzheimer’s disease. The changes
may be even less distinct in other
dementia-inducing brain diseases.
Pain assessment in dementia
patients
Even patients with fairly severe
dementia are usually able to ex-
press verbally the pain they suf-
fer and to understand the ques-
tions posed in relation to their
pain (13). In the case of very ad-
vanced dementia, observational
methods and the interpretation
of behavioural changes may have
to be resorted to. The widely
used Resident Assessment Instru-
ment (RAI) system, with compa-
rable tools developed for exam-
ple for the needs of long-term in-
stitutional care and acute treat-
ment (14, 15), also contains an
assessment of the pain the pa-
tient is experiencing. The RAI
system assesses the intensity and
density of pain based on the pa-
tient’s own report (and also on
the assessor’s report when diffi-
culties with comprehension or
communication are present).
Several different, but so far
inadequately standardised, as-
sessment tools have been devel-
oped for assessing the pain of pa-
tients with dementia and lack of
communicative ability (16–18).
The Pain Assessment in Ad-
vanced Dementia Scale
(PAINAD) is one of these tools,
based on the structural observa-
tion of behavioural changes
caused by pain (19). The pain as-
sessment tool PAINAD consists
of five observation categories:
breathing, vocalisation, facial ex-
pressions, body language and
consolability. Each category con-
tains a scale of three points (0–2)
for the behavioural changes
caused by the pain (Table 1).
Reijo Tilvis
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Pain assessment is carried out
during observation periods last-
ing for about 5 minutes. The pain
is assessed by scoring total points
in between 0 and 10, where 0 in-
dicates a pain-free state and 10
the most severe pain. The level of
pain is assessed before and during
the administration of treatment.
We carried out a survey re-
cently into the prevalence of pain
in elderly hospital patients with
dementia in both outpatient hos-
pital clinics and long-term care
settings in Helsinki (20). In emer-
gency hospital settings (n=95),
according to the RAI-AC scale,
51% of the patients had suffered
from pain during last 24 hours
(Table 2). Using the PAINAD
scale, however, indications of
pain were observed in 47% of
patients at rest and 77% of pa-
tients during administration of
treatment. The two scales con-
formed with one another at the
state of rest in only a little over
half of the patients. Almost every
alternate person among those
judged as pain-free by the RAI-
AC scale were found to experi-
ence pain when measured against
the PAINAD scale. During the
administration of treatment, as
many as more than two thirds of
those patients judged as pain-free
by the RAI-AC scale were appar-
ently suffering from pain when
assessed against the PAINAD
scale. The patients’ cognitive level
was not specified in the survey,
but in emergency hospital settings
the patients were, as a rule, able
to answer questions about pain in
the RAI system by themselves. 
Patients in long-term care set-
tings (n=202) were, as a rule, to-
tally unable to answer questions
about pain on the RAI-LTC scale,
and the results were based on the
joint assessment made by the pa-
tients’ nurses. Measured by the
PAINAD scale pain at rest oc-
curred in 43% and pain during
administration of treatment in
75% of the patients. As for the
daily pain, the scales agreed in
only about a third of the patients,
and the agreement between the
scales otherwise was over 50% as
it was with acute geriatrics ward
patients. The proportion of pa-
tients suffering from pain when
measured by the PAINAD scale
during rest was about 40% and
during the administration of
treatment was about 70% of
those judged as pain-free by the
RAI-LTC scale. A majority of
those judged as pain-free at rest
by the PAINAD scale appeared to
suffer from pain during the ad-
ministration of treatment. In a
small proportion of these patients
the pain during the administra-
tion of treatment was in fact very
Table 1. Pain Assessment in Advanced Dementia Scale (PAINAD-scale).
0 1 2
Breathing Normal and unnoticeable. Breathing occasionally troblesome. 
Short periods of hypervetilation.
Breathing loud and troublesome. 
Long periods hyperventilation. 
Cheyne-Stokes-type of breathing.
Uttering No uttering of sounds. Content
uttering of sounds.
Occasional wailing or moaning. 
Moaning or complaining, quiet talk.
restless shouting. Loud wailing or 
moaning. Crying.
Expressions Smiling or expressionless. Sad. Frightened. Severe. Grimacing.
Body language Restful. Tense. Anxious walking. 
Restless movements.
Rigid. Hands in a fist. Knee up. 
Pulling or pushing. Jerking.
Consolability No need to be consoled. A sound or a touch districts the attention
elsewhere or calms down.
Consolation, distraction of attention or
calming do not have an effect.
Table 2. Recording of pain with the PAINAD scale at rest, during treatment measures, and in the
RAI system (%).
PAINAD at rest PAINAD during treatment Total pain in
RAI 
Pain No pain Pain No pain
Pain in acute geriatry  in-patients during the previous 24 hours (n = 95)
Pain in RAI 25,3 25,3 43,2 7,4 51
No pain in RAI 22,1 27,4 33,7 15,8 49
Total pain in 
PAINAD
47 53 77 23 100
Pain in long-term hospital patients less often than daily (n = 202)
Pain in RAI 23,8 21,8 39,1 6,4 46
No pain in RAI 19,3 35,1 35,6 18,8 54
Total pain in 
PAINAD
43 57 75 25 100
Pain in long-term hospital patients daily during the previous week (n = 202)
Pain in RAI 7,9 5,9 12,4 1,5 14
No pain in RAI 35,1 51 62,4 23,8 86
Total pain in 
PAINAD
43 57 75 25 100
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severe. Nearly 95% of the pa-
tients assessed as pain-free during
the administration of treatment
were also classed as pain-free at
rest.
The pain assessments by the
RAI system and the PAINAD
scale therefore differed signifi-
cantly from one another in elder-
ly patients with mild in acute
care or severe dementia in long
term care. A survey of the results
of the pain measurement scales
separately shows that they both
reported nearly every alternate
subject in our material as suffer-
ing from pain at least weekly, but
there was mutual agreement be-
tween the RAI system and
PAINAD scale about classifying
only about one in every four pa-
tients as suffering from pain. The
PAINAD scale also found indica-
tions of pain during the adminis-
tration of treatment in almost
three out of four patients who
had been judged as pain-free by
the RAI system.
Interpretation of the results is
also made difficult by the ab-
sence of an objective standard,
called the golden standard, for
the assessment of pain in patients
with severe dementia. In these
patients, however, the world-
wide proof of the reliability and
validity of the PAINAD scale is
already encouraging (16–18).
The introduction of the PAINAD
scale and the carrying out of as-
sessments during the administra-
tion of treatment, however, ap-
pears to increase the reporting of
pain, which has resulted for ex-
ample in the increased use of
analgesics (21). In addition, the
patient’s own report has been
considered inappropriate as a
pain assessment method in pa-
tients with moderate or severe
dementia, as the patients’ own
reports have been found to devi-
ate distinctly from both the as-
sessments made by the care per-
sonnel and the results obtained
by the PAINAD scale (22). In the
same way, the RAI system has
been found to underrate the pain
experienced by residents with
cognitive impairment in long-
term care settings (23). The sur-
vey shows that the pain-free state
detected by the PAINAD scale es-
pecially during the administration
of treatment would appear to
give a fairly strong indication of
the patient’s true pain-free state.
Nevertheless, further studies are
required before the PAINAD scale
can be widely recommended as
the only pain assessment method
in elderly patients with dementia.
The pain in dementia patients,
too, is always a subjective experi-
ence; and all pain assessment
methods are inadequate, especial-
ly in patients with an inability to
communicate. Instead of pain, or
together with it, the patient’s be-
havioural changes may also have
other underlying factors, such as
thirst, need to go to the toilet,
purposeless level of alertness, de-
pression, psychosis or uncomfort-
able clothing. Behavioural chang-
es in dementia patients may also
vary considerably. It is recom-
mended that while observational
behavioural methods of pain as-
sessment are being developed and
evaluated in future, emphasis
should be placed in several differ-
ent observational sections on the
scales by which behavioural
changes are observed. Even
though pain scales which struc-
turally observe the behavioural
changes can easily be considered
to interpret the dementia patient’s
general discomfort as pain, the
scales do nevertheless allow an-
other opportunity to stop and
look at the patient and to make a
better assessment of the cause of
the variation shown by the pain
scale.
Should pain treatment be 
improved?
There are ethical reasons as such
for making an effort also to alle-
viate pain in the case of dementia
patients if a pain-free status can-
not be guaranteed. However, very
few controlled clinical trials have
been carried out to test the effects
of analgesic therapies on the pain
behaviour of demented patients
or on their other consequences.
Two retrospective reviews have
indicated an increase in analgetics
use to be associated with a de-
crease in the use of antipsychotics
(24, 25). The changed degree of
agitation (Cohen-Mansfield Agi-
tation Inventory) has been as-
sessed in 25 dementia patients,
judged as pain-free, who were
given a placebo over a period of
four weeks, followed by a small
dose of morphine with a long-
term effect for the subsequent
four weeks (oxicodone 10 mg 
1 x 2). Some of the agitation was
presumed to be due to unidenti-
fied pain and the symptoms pos-
sibly to be alleviated by analgetic
therapy. This did not happen,
however, even though an obser-
vation fitting in with the hypoth-
esis was, in fact, identified in a
subgroup of the over 85-year-
olds. It was speculated that only
the oldest age group had received
a dose of morphine which was
adequately high. A corresponding
test was carried out with parac-
etamol, which was administered
(at 3 x 1,000 mg) intermittently
with a placebo, both of them in
blind trials for a period of four
weeks (27). During the course of
analgetics the patients were mov-
ing about more and they were so-
cially more active. Unpredictably,
the symptoms of agitation were
not decreased and the mental
wellbeing was not improved.
Neither was the use of antipsy-
chotics diminished. On examin-
ing 39 dementia patients (MMSE
4.3 ± 5) with degenerative arthri-
tis, there was no difference found
in the treatment of pain between
regular and as-required paraceta-
mol medication (28). The daily
dose of 2,600 mg used was nev-
ertheless inadequate for reducing
discomfort when compared with
the placebo group. As with other
issues, new, more extensive stud-
ies are urgently needed to review
this one. 
Literature: See page 7.
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Large-scale clinical trials have
shown that statins are effective
and safe cholesterol lowering
compounds (1-3). More recent
data suggest that aggressive lipid
lowering results in even greater
reductions of atherosclerotic
complications. Thus, more pa-
tients are titrated to higher doses
of statins to reach the new ag-
gressive goals of LDL-cholesterol
reduction. However, aggressive
treatment with high dosages has
argued to increase the risk of
statin-induced myopathy, there-
fore, identification of patients
likely not to tolerate the treat-
ment is of great clinical interest.
Recently, several key papers have
been published addressing statin-
induced myopathy. One of the
messages seems to be that the
muscle effects are more frequent
in clinical practise than estimated
based on clinical trial reports. In
a systematic review of randomi-
sed clinical trials Kashani et al.
concluded that statin therapy is
associated with a small excess
risk of transaminase elevations,
but not of myalgias, rhabdomyol-
ysis, or withdrawal of therapy
compared with placebo (4).
However, the authors notified
that further study is necessary to
determine whether the results
from published clinical trials are
similar to what occurs in routine
practice, particularly among pa-
tients who are older, have more
severe comorbid conditions, or
receive higher statin doses than
most patients in trials they ana-
lyzed for the review. In fact,
Bruckert et al. had earlier pub-
lished a large-scale, comprehen-
sive investigation of risk, cause,
nature and management of mus-
cle symptoms in patients receiv-
ing high-dose statin therapy in
clinical practice (5). One of the
important observations of this
PRIMO-study was that the fre-
quency of mild and moderate
muscle symptoms with high dose
statin therapy might be more
common and exert a greater im-
pact on everyday life than previ-
ously thought. In the PRIMO
study population (n=7,924 pa-
tients receiving high dose statin
treatment), 10.5% of the patients
on high dose statin therapy com-
plained of muscle pain, while the
highest rate (18.2%) was associ-
ated with high dose simvastatin
treatment. Thus, well-defined ar-
guments can be stated to support
muscle safety of statins, but also
to demonstrate a common harm-
ful impact on everyday life. 
A number of smaller studies
have focused to evaluate the
mechanisms of possible statin ef-
fects in muscle. Phillips et al.
have shown that some patients
who develop muscle symptoms
while receiving statin therapy
have demonstrable weakness and
histopathologic findings of myo-
pathy despite normal serum crea-
tine kinase (CK) levels (6). Fur-
thermore, we have observed sig-
nificant changes in skeletal mus-
cle cholesterol metabolism and
respiratory chain enzyme activity
in asymptomatic patients on high
dose statin treatment without ele-
vated serum CK levels (7). Based
on these observations it seems
likely that significant alterations
may occur in muscle metabolism
in patients on statins without sig-
nificant changes in the CK levels.
A lack of reliable biomarker
makes it difficult to interpret
clinical study results on statin
safety based mainly on CK mea-
surements. Better biomarkers
would also help physicians to de-
cide whether patients’ muscle
complains without evidential CK
elevation necessitate any changes
in their lipid-lowering treatment.
To study more closely metabolic
effects in muscle during high dose
statin treatment, we performed
bioinformatics analysis of whole
genome expression profiling of
muscle specimens and UPLC/MS
based lipidomics analyses of plas-
ma samples obtained in the
above mentioned randomized tri-
al from patients either on high
dose simvastatin (80 mg), ator-
vastatin (40 mg), or placebo (7).
We recorded 111 differentially
expressed genes (1.5-fold change
and p-value < 0.05) in the high
dose simvastatin group, while ex-
pression of only one and five
genes was altered in the placebo
and atorvastatin groups, respec-
tively (8). The Gene Set Enrich-
ment Analysis identified 23 af-
fected pathways (False Discovery
TABU 3. 2007 55
In English
In English
Rate q-value < 0.1) in muscle fol-
lowing high dose simvastatin, in-
cluding eicosanoid synthesis and
phospholipase C pathways. We
also found that the plasma
lipidomic changes following sim-
vastatin treatment correlate with
the muscle expression of the
arachidonate 5-lipoxygenase-acti-
vating protein. Our results
demonstrated that high dose sim-
vastatin affects multiple metabol-
ic and signalling pathways in
skeletal muscle, which may lead
to unexpected metabolic effects
in non-hepatic tissues. Intriguing-
ly, the plasma lipidomic profile
may serve as a highly sensitive
biomarker of statin-induced
metabolic alterations in muscle
and may thus allow us to identify
patients who should be treated
with a lower dose to prevent a
possible toxicity.
The exact mechanism of
statin-induced myopathy is still
unclear. We do know rather well
that some diseases such as hy-
pothyroidism, liver dysfunction
and diabetes are increasing the
risk of muscle complications of
statin treatment. Exercise, alco-
hol or infections may also in-
crease the risk. Some patients are
obviously having a higher sys-
temic bioavailability for statins
possibly due to numerous drug
interactions or due to some un-
known (possibly genetic) factors
in the metabolism of different
statins. Another option could be
a pre-existing molecular or meta-
bolic defect. Troseid et al. have
described four related patients
with statin-associated muscle
symptoms and normal creatine
kinase levels (9). In their pa-
tients, two (mother and son) had
pathological myopathy related
findings on EMG and muscle
biopsies also showed evidence of
mitochondrial pathology. A third
patient (daughter) had slight 
myopathic findings on EMG and
muscle biopsy. In a fourth pa-
tient, there were no pathological
findings. The authors concluded
that an inherited vulnerability,
possibly a mitochondrial pathol-
ogy, might cause or aggravate
symptoms in some statin-treated
patients. As well, in the PRIMO
study family history of muscular
symptoms with or without lipid-
lowering therapy appeared as a
significant predictor of statin re-
lated muscle pain in a multivari-
ate model. Thus, a genetic predis-
position may play a significant
role in the development of statin
related muscle symptoms.
To study whether statin treat-
ment could aggregate pre-existing
mitochondrial pathologies we de-
termined whether muscle mito-
chondrial DNA (mtDNA) levels
are altered during statin therapy
and, therefore, quantified 
mt-DNA in 86 skeletal muscle
biopsy specimens collected as
part of a previously mentioned
clinical trial of high-dose simvas-
tatin or atorvastatin versus place-
bo (10). We determined mtDNA/
nuclear DNA (nDNA) ratio in
muscle biopsies collected before
and after 8 weeks of treatment
with placebo (n=14), high-dose
atorvastatin 40 mg/day (n=15),
or high dose simvastatin 80
mg/day (n=14). At baseline, mtD-
NA/nDNA ratios were not differ-
ent between the three treatment
groups, however a significant de-
crease (-47%) in muscle mtDNA
levels was observed in the sim-
vastatin group between baseline
and the 8-week follow-up (Fig.).
Indeed, 7/14 patients in the sim-
vastatin group showed a greater
than 50% decrease in mtDNA at
follow-up, whereas only 2/15
and 0/14 such decreases occurred
in the atorvastatin and placebo
groups, respectively. 
This finding was in accordance
with muscle mitochondrial respi-
ratory chain-enzyme complex ac-
tivity assays in selected partici-
pants suggesting decreased total
mitochondrial volume or fewer
mitochondria per cell in the sim-
vastatin group. The selective
elimination of mitochondria, in-
cluding mtDNA, has been de-
scribed in apoptotic cells (11)
and in cells exposed to inhibitors
of mitochondrial function (12).
Our results suggest that statin
therapy can be associated with
mtDNA depletion, probably
caused by the treatment itself. It
is possible that in our patients,
high-dose simvastatin treatment
induced stress on skeletal myo-
cytes that led to the elimination
of mitochondria and reduced lev-
els of mtDNA. Drawing a paral-
lel with metabolic mitochondrial
diseases, such mtDNA depletion
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Figure. Changes in mtDNA/nDNA ratio after 8 weeks of high-dose statin treatment.
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may contribute to mitochondrial
dysfunction and play a role in
statin induced myopathy. A key
feature of this study was that no
subjects reported muscle weak-
ness or pain or showed elevated
serum CK at follow-up, despite
significant decreases in muscle
mtDNA in those treated with
simvastatin. This would be con-
sistent with the ‘’threshold effect’’
observed in mtDNA-depletion
disease, whereby clinical muscle
symptoms appear only after mtD-
NA levels fall below 25–30% of
normal. The observations herein
obviously spark interest in mea-
suring muscle mtDNA levels in
patients who experience myopa-
thy while on statin therapy, espe-
cially in the light of the magni-
tude of the mtDNA decrease ob-
served here over a very short pe-
riod of asymptomatic statin treat-
ment. 
Mukhtar and Reckless have
listed four potential statin my-
opathy mechanisms in their re-
cent review: Depletion of intracel-
lular cholesterol leading to calci-
um influx; inhibited protein syn-
thesis, signal transduction and
metabolism due to decreased
mevalonate acid and its metabo-
lite concentrations; reduced
ubiquinone (coenzyme Q10) con-
centrations; and enhanced apop-
tosis (13). Expression of genes re-
lated to cholesterol metabolism
or mevalonate pathway was only
modestly affected by statins in
our study. Thus, our present data
do not directly support the view
that statins would cause mito-
chondrial dysfunction by reduc-
ing ubiquinone, a mitochondrial
coenzyme with a cholesterol syn-
thetic pathway derived side chain,
due to inhibition of HMG-CoA
reductase in the muscle. Similarly
we were not able to provide evi-
dence that statins would lead to
inhibition of protein synthesis,
signal transduction and metabo-
lism due to decreased muscle
mevalonate acid. Since our pa-
tients did not have any signs of
clinical myopathy and muscle
damage, we were not able to
judge the significance of early
proapoptotic markers during the
course of the myopathy. Howev-
er, in the GSEA analysis several
pro-apoptosis pathways already
appeared with significant FDR q-
values at these early stages and,
therefore, the present results sup-
port the role of proapoptosis
pathways in statin myotoxicity.
Furthermore, the hypothesis of an
increased Ca2+ influx as a media-
tor of statin induced toxicity is
supported by the significant up-
regulation of phospholipase C
pathway and by the dysregulation
of genes encoding for calcium
binding proteins in our study. An-
other hallmark of high dose sim-
vastatin effect in muscle was the
activation of pro-inflammatory
pathways such as eicosanoid syn-
thesis. However, our results can-
not reveal the actual trigger lead-
ing to impaired mitochondrial
function and induction of these
proinflamatory pathways. A simi-
lar gene expression experiment
was also performed on healthy
volunteers by Urso et al. (14).
They observed only little effect
on gene expression at rest due to
4-week atorvastatin (80 mg/d)
treatment similar to our results.
However, when combined with
exercise, 56 genes were expressed
differently with 18% involved in
the ubiquitine-proteasome path-
way. In addition, 20% of the af-
fected genes were related to pro-
tein folding, catabolism and
apoptosis.
Based on our data at the doses
studied as well as clinical reports
mentioned above, simvastatin
and atorvastatin seem to differ in
their effect on muscle metabo-
lism. However, the specific prop-
erties of these drugs that lead to
different effects on muscle mito-
chondria are unknown. Despite
the risk of myopathy, which ap-
pears increased in individuals
with an underlying genetic sus-
ceptibility for metabolic myo-
pathies (9,15), statin therapy is
clearly beneficial to the majority
of hypercholesterolemic patients
at risk for cardiovascular disease.
However, the results of this study
reinforce the need to closely mon-
itor closely patients receiving
statin therapy, especially those on
high-dose, and to identify a sensi-
tive and reliable clinical marker
of statin toxicity. Recently, the
United States’ National Lipid As-
sociation’s Muscle Safety Expert
Panel has pointed out the need
for a validated measuring instru-
ment for statin-related muscle
complaints as existing methods
may lack sensitivity and specifici-
ty. Our combined transcriptomic
and lipidomic analysis provides
bona fide sensitive biomarkers of
statin induced metabolic changes
in muscle potentially useful to
identify patients at risk early
enough to prevent actual muscle
damage. These biomarkers are
now available for further valida-
tion in patients with proven
statin-induced myopathy.
Literature: See page 15.
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Adverse drug reactions of statins
Radhakrishnan Rajaratnam
Senior Medical Officer
National Agency for Medicines
Marja Forsell
Pharmacovigilance Officer
National Agency for Medicines
Until the end of December 2006, the Finnish National ADR Register received 513 reports in which
statins were considered as suspect medication for the ADR. Majority of the reports included well-
known adverse reactions of statins such as musculoskeletal, hepatobiliary, and gastrointestinal disor-
ders. Serious cases are rare and mostly associated with high dose statin therapy and interactions.
HMG CoA reductase inhibitors,
statins are originally fungal
metabolites, and the earliest
statin, compactin, was discovered
from Penicillium citrinum in the
mid 1970s. Statins lower serum
cholesterol levels by inhibiting
cholesterol synthesis which in
turn increases hepatic low density
lipoprotein (LDL) receptor ex-
pression and the clearance of
atherogenic LDL. Large ran-
domised clinical trials have con-
vincingly shown that effective
serum cholesterol reduction with
statins decrease significantly
coronary mortality in primary
and especially secondary preven-
tion. Due to intensive therapy to
achieve these goals the potential
for increased risk of ADRs with
such therapy increase.
The well known adverse drug
reactions related to statins thera-
py include hepatobiliary, muscu-
loskeletal, and gastrointestinal
disorders. Rare adverse effects in-
clude rash, chronic fatigue, hy-
persensitivity and neuropathy.
Memory loss, sleeping disorders
and malignancies have also been
reported. Some, like rhabdomyol-
ysis and liver failure, can be fatal.
In 2002, marketing authorisation
of cerivastatin was withdrawn be-
cause of concerns regarding an
increased risk of rhabdomyolysis.
Statins are authorised in Fin-
land since 1988. At present, six
statins, atorvastatin, fluvastatin,
lovastatin, pravastatin, rosuvas-
tatin and simvastatin are avail-
able in the Finnish market. Num-
ber of generic products are in-
creasing continuously and there
are 12 generic products of lovas-
tatin, 22 generic products of
pravastatin, and 28 generic prod-
ucts of simvastatin.According to
the wholesale consumption of
statins in Finland 2006, simvas-
tatin is widely used, followed by
atorvastatin.
During 1988–2006, the
Finnish ADR Register received
513 reports in which statins were
considered as suspect medications
for the ADR (Table 1). A total of
857 ADRs were reported, and
141 cases were considered as seri-
ous. Majority of the reports were
received of  atorvastatin, fol-
lowed of simvastatin, fluvastatin,
rosuvastatin, lovastatin and
pravastatin. The causal relation-
ship with statins is not estab-
lished with all reported ADRs.
Cases in which statins were re-
ported as concomitant medica-
tion are not discussed here.
Common ADRs
As expected, musculoskeletal, he-
patobiliary, skin and gastroin-
testinal ADRs were frequently re-
ported for each statin (Table 1).
Of the 215 ADRs of myalgia
and/or CK increased, 56 reactions
were associated with simvastatin,
27 with lovastatin, 9 with pravas-
tatin, 34 with fluvastatin, 44 with
atorvastatin, and 45 with rosu-
vastatin. In a suspicion of myopa-
thy during statin therapy, serum
CK level should be measured and
if it exceeds 5 fold maximum ref-
erence value the therapy should
be discontinued. 
Uncommon ADRs
Sleep disorders, insomnia, para-
somnia, memory loss, micturition
disorders, erectile dysfunction,
depression, and malignancies
have also been reported in pa-
tients taking statins. Some of the
SPCs contain these adverse effects
in the section 4.8. Whether these
ADRs are likely to be class effects
have been discussed in PhVWP of
EMEA. Atorvastatin was associ-
ated with increased risk of haem-
orrhagic stroke in a recent pub-
lished SPARCLE study. In a pub-
lished PROSPER study, pravas-
tatin was associated with new
malignancies, although the latter
was not associated with simvas-
tatin during 10-years follow up in
Scandinavian 4S study.  In our
national register, one case of
prostate cancer was identified in
a patient with atorvastatin thera-
py. Another 59 years old male
patient experienced recurrent li-
posarcoma and leiomyosarcoma
after approxymately 1 year treat-
ment with rosuvastatin. The ner-
vous psychiatric disorders of in-
terest and erectile dysfunctions
are presented in Table 2. 
Hypersensitivity  
Drug-induced hypersensitivity re-
actions are immunologically me-
diated and statins have been asso-
ciated infrequently with a variety
of these reactions. Generally ur-
ticaria, angioedema and dys-
pnaea are the most frequent
symptoms of hypersensitivity. In
Finnish National ADR register, in
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addition to urticaria, arthralgia
and arthritis were identified with
high frequency for all statins ex-
cept pravastatin (Table 3). Very
few cases of polymyalgia rheum-
atica were linked to lovastatin
and rosuvastatin therapy. With
regard to pravastatin only one
case of autoimmune haemolytic
anaemia was reported. Although
hypersensitivity is contraindicat-
ed in the SPCs of all statins it is
important for healthcare profes-
sionals to recognise these mani-
festations of hypersensitivity be-
cause they have been rarely asso-
ciated with HMG-CoA in-
hibitors. 
Interactions
A total of 8 suspected interac-
tions were reported (Table 4).
Rhabdomyolysis was reported in
5 cases and associated with high
dose statin therapy. The cyto-
chrome P-450 system is involved
in statin metabolism, although
its functions differ among
statins. Drugs that can inhibit
cytochrome P-450-mediated me-
tabolism of statins have potential
for clinically significant interac-
tion. Few inhibitors are con-
traindicated for statin treatment.
If a concomitant use is required,
it has been suggested that the
initiation dose of statin should
be minimal and patients should
be closely monitored for ADRs
* Including 1 fatal case.
**  In few reports more than one statin was suspected.
Table 3. Hypersensitivity reactions
Atorvastatin Fluvastatin Lovastatin Rosuvastatin Simvastatin
Urticaria 5 1 1 1 3
Angiooedema 1
Polymyalgia rheumatica 2 1
Lupus like reaction 1 1
Photosensitivity reaction 1 2
Arthralgia 4 6 3 3 6
Arthritis 1 1 1 2
Eosinophilia 1 1
Vasculitis 1 1
Table 1. Most frequently reported adverse drug reactions  (ADRs) according  to  System 
organ classification (SOC]
Drug Number of
reports **
No of 
serious 
cases
No of
ADRs
System organ classification (SOC) term
( 4 most common) ,
(incl. laboratory terms)
No of
ADRs
Simvastatin 123 33 212 Musculoskeletal 87
Skin and subcutaneous tissue disorders 36
Hepatobiliary 23
General disorders and admi nis tration
site condition
15
Lovastatin 64 9 105 Musculoskeletal 36
Hepatobiliary 16
Psychiatric disorders 15
Gastrointestinal 10
Pravastatin 24 7 37 Musculoskeletal 21
Hepatobiliary 8
Psychiatric disorders 3 
Eye and  ear 3
Fluvastatin 94 28* 172 Musculoskeletal 50
Hepatobiliary 43
Gastrointestinal 24
General disorders and administration
site condition
10
Atorvastatin 131 44* 205 Musculoskeletal 63
Hepatobiliary 36
Skin and subcutaneous tissue disorders 30
Nervous disorders 19
Serivastatin 7 1 10 Different SOCs 10
Rosuvastatin 75 19* 116 Musculoskeletal 55
Hepatobiliary 15
Skin and subcutaneous tissue disorders 11
General disorders and administration
site condition
9
Table 2. Nervous psychiatric disorders and
erectile dysfunctions associated  with the
use  of statins.
Simvastatin depression 1 
sleep disorders 1
Lovastatin depression 4 
insomnia 5
parasomnia 1
sleep disorders 2 
erectile dysfunction 1
Pravastatin parasomnia 1
sleep disorders 1 
Fluvastatin memory loss 1
insomnia 2
Atorvastatin insomnia 3
erectile dysfunction 3 
Rosuvastatin memory loss 1
insomnia 1
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especially for myopathy. 
Due to additive risk, the con-
current use of HMG-CoA reduc-
tase inhibitors and fibric acid de-
rivatives has resulted in fulminant
rhabdomyolysis as early as three
weeks after the initiation of ther-
apy. Ezetimibe may also potenti-
ate myopathy associated with
statin therapy. Therefore these
combination therapies should be
considered only if the potential
benefit outweighs the increased
risk of adverse effects. 
Are the ADRs reversible?
Approxymately 300 patients re-
covered mostly after discontinua-
tion of statin therapy, and 150
patients have not recovered de-
spite statin withdrawal at the
time of the reporting.  In 55 ADR
reports outcome was not report-
ed. Frequency of recovery from
serious ADRs of special interest
are provided in the Figure 1. Ap-
proximately half of the rhab-
domyolysis and pancreatitis cases
and majority of the neuropathy
and joint related disorders cases
did not have favourable outcome
at the time of the reporting. One
fatal rhabdomyolysis was report-
ed. Most of the ADRs including
hepatic enzyme elevation and my-
opathy are mostly reversible after
discontinuation of statins.
Cases with fatal outcome
Since 1973, a total of 630 ADR
reports with fatal outcome were
received in Finnish ADR register.
Among these reports only in 3 re-
ports, statins was suspected to
have association with patients’
death. A 76-years old patient
with concomitant fluconazole, an
inhibitor of CYP3A4 experienced
progressive myopathy, rhabdomy-
olysis and renal failure and suc-
cumbed to multiorgan failure fol-
lowing the change of pravastatin
to atorvastatin. An interaction
between fluconazole and atorvas-
tatin was suspected in this case
although the patient had history
of previous surgery for a rup-
tured aortic aneurysm followed
by rhabdomyolysis and renal in-
sufficiency. Atorvastatin, but not
pravastatin undergoes significant
CYP3A4-mediated metabolism.
In the second case, a 41 years
male patient with rosuvastatin 20
mg daily dose and concomitant
ezetimibe experienced a sudden
death after a cross country walk.
No further information was
available. In the third case, a 58
years old female patient died due
to hepatic cirrhosis and acute liv-
er failure after 4 months treat-
ment with fluvastatin.  Fatal
rhabdomyolysis and acute liver
failure are very rare adverse reac-
tions associated with statin thera-
py especially in high doses and in
the presence of drug interaction.
In summary, HMG-CoA in-
hibitors are among the most fre-
quently prescribed medications
and are generally well tolerated.
A few patients experience re-
versible clinical and biochemical
adverse effects including elevation
of transaminases or creatine ki-
nase or myopathy. Adverse effects
occur more frequently with the
use of the higher doses and in the
presence of other drugs (eg. cic-
losporin, erythromycin, ketocona-
zole, fibrates or ezetimibe). Dose
titration is advocated. Awareness
of the ADRs and clinically signifi-
cant interaction among clinicians
continues to be important, and
counceling patients on possible
adverse effects is recommended.
By reporting rare ADRs, the safe-
ty profile of statins still can be
expanded. 
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Table 4. Interactions.
Patient Statin Concomitant medication ADR Latency
52-y. M simvastatin 80 mg/day ciklosporin rhabdomyolysis approx 1 month after  ciclosporine
51-y. F simvastatin 80 mg/day fluvoxamine rhabdomyolysis approx 1 month after simvastatin
85-y. F simvastatin 80 mg/day clarithromycin rhabdomyolysis approx 1 week after  clarithromycin
F simvastatin 10 mg/day lercanidipine alopaecia approx 1 month after lercanipine
54-y. F lovastatin 80 mg/day itraconazol rhabdomyolysis approx 2 weeks after itraconazole
45-y. M fluvastatin 20 mg/day ethanol prolonged alkohol effect
67-y. M atorvastatin 80 mg/day gemfibrozil, eplerenone renal insufficiency, CK increased after 1 m after increasing  eplererone
77-y.  atorvastatin 40 mg/day fluconazol rhabdomyolysis
Fig. Recovery from serious ADRs of interest 
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his own accord on 5.4.2005 and
noticed on 30.5.2005 that his
memory was restored to normal.
He was aiming at an ideal out-
come of treatment and so spon-
taneously resumed the treatment
with rosuvastatin on 1.9.2005.
This led in consequence to a dis-
tinctly reduced memory function
by as early as 10.9.2005. He
then started taking a dose of 10
mg on alternate days, and even-
tually withdrew from rosuvas-
tatin therapy altogether.
The case was thought to be
possibly of a drug-specific char-
acter, and the water soluble rosu-
vastatin was therefore replaced
by fluvastatin in a depot formula
80 mg x 1 on 29.9.2005.  Fol-
lowing three months’ therapy he
again noticed distinct impair-
ment of his memory and the
drug was this time replaced by
ezetimib 10 mg, introduced on
1.12.2005. After half a year’s
therapy with ezetimib he has no
longer suffered from memory im-
pairment and the lipid profile on
4.4.2006 was excellent: choles-
terol 4.1 mmol/l, LDL choles-
terol 1.7 mmol/l, HDL choles-
terol 2.1 mmol/l, triglyceride 0.6
mmol/l, and the conclusion is
that the memory disturbance is
not associated with the levels of
the lipids.
Follow-up studies have indi-
cated a reduced risk of dementia
in patients on statins. On the one
hand, the protection mechanism
is thought to be provided by in-
hibition of amyloid production
and consequently inhibited
plaque formation in the brain
(1). There are, on the other
hand, reports of statin-induced
memory disturbances with the
suggested mechanism being the
inhibition of myelin production,
which leads to the demyelinisa-
tion of neurofibrils (2). Further
studies have not, however, been
able unequivocally to prove bene-
ficial anti-amyloid effects (3). Pa-
tients on statins generally suffer
from cardiovascular diseases and
associated cerebrovascular acci-
dents, which may be confusing
when looking into the causes of
memory disturbances. Our pa-
tient, who had suffered the ad-
verse reaction, is showing no
signs of cerebrovascular acci-
dents.
It is a question of a very rare
adverse reaction. The most exten-
sive review found in the literature
concerns 60 patients. About one
third of the memory disturbances
were cases of sudden loss of
memory of the transient global
amnesia type, and two thirds
were non-specific memory distur-
bances (3). The median time peri-
od between the initiation of med-
ication and realisation of a mem-
ory disturbance was 60 days.
Memory disturbances have been
reported in association with the
use of at least the following
statins: simvastatin, lovastatin,
fluvastatin, pravastatin, cerivas-
tatin and rosuvastatin (4, 5). This
rare adverse reaction does not
have a great significance in pre-
scribing when treating the large
group of high risk patients, but it
should be borne in mind in indi-
vidual cases where adverse reac-
tions occur.
Literature: See page 20.
Own observation of an adverse reaction
Memory disturbance caused by statins
John Melin
Specialist, Internal Medicine
Head of Department
Keski-Suomi Central Hospital
A male born in 1945, with acad-
emic education and a managerial
position, was admitted for con-
sultation with an internal medi-
cine specialist due to high blood
pressure in August 2004. He was
bodily obese in spite of active
exercise (even running marath-
ons) and the correct constitu-
ents of his diet. Anti-hyperten-
sive treatment was initiated with
ramipril 10 mg, with lerkanidip-
ine 10 mg and acetylsalicylic
acid 100 mg added to the treat-
ment on 12.11.2004. Hyperten-
sion was subsequently adequate-
ly controlled and the patient’s
condition was good. Full control
of the risk factors, however, was
not achieved with non-pharma-
ceutical measures as the patient’s
cholesterol levels remained high
albeit reduced: 7.2–5.7 mmol/l,
LDL cholesterol 4.5–3.4 mmol/l,
HDL cholesterol 2.2–1.9 mmol/l,
triglyceride 1.1–1.0 mmol/l. Ro-
suvastatin 10 mg was added as
an adjunct to the therapy on
2.12.2004.
Initially the patient could not
observe any adverse effects of
the medication given, but after
three months, in March 2005, he
started suffering from significant
memory impairment. He began
to forget the names of his col-
leagues, which resulted in em-
barrassing situations.
According to the standards at
the time, a good lipid level was
achieved on 23.3.2005: choles-
terol 5.0 mmol/l, LDL choles-
terol 2.2 mmol/l, HDL choles-
terol 2.5 mmol/l, triglyceride 0.6
mmol/l. The patient subsequent-
ly stopped taking rosuvastatin of
Disulfiram has already for a long
time been in use in the withdraw-
al treatment of alcoholism, ad-
ministered both in tablet form
and, previously, as implants. Its
use has somewhat increased in
recent years, and last year it was
used daily by about 4 400 per-
sons. There is definitive proof of
the efficacy of disulfiram when it
is used under supervision and
when the medication is accompa-
nied by supportive treatments.
The drug is without effect when
it is used unsupervised.
Safety  
Disulfiram apparently also in-
hibits several liver enzymes in-
cluding the CYP2E1 enzyme. In
addition to pharmacokinetic in-
teractions, it has been found for
example to possess a hypotensive
effect, and while it interacts with
drugs having a cardiac and car-
diovascular effect it apparently
also causes confusion in con-
comitant use with antidepres-
sants.
Disulfiram is known to have
occasioned encephalopathy, in
which case the symptoms may
look like psychiatric symptoms;
furthermore, psychoses, confu-
sion, sleep disturbances, halluci-
nations, depression and anxiety
have generally been occasioned in
users. Peripheral neuropathy has
occurred as well as other neuro-
logical symptoms (optic neuritis,
headache, vertigo, ataxia and
spasms); rash has also been re-
ported.
Liver function disorders have
been the most common adverse
reactions reported to the Nation-
al Agency for Medicines. A total
of 34 adverse reactions were re-
ported, 24 of which involved liv-
er function: in nine cases elevated
liver values were reported, 12
cases involved hepatitis, and two
of these were presumed to have
been fatal. Two reports of liver
necrosis have been received. Up
until April this year, as many as
four reports had been received of
severe liver effects in patients
who had been on disulfiram ther-
apy.
The instructions in the sum-
mary of product characteris-
tics must be followed
The adverse effects and condi-
tions for effective use of the drug
have been presented in the SPC
for disulfiram. The therapeutic
indications state that the product
is used as a supportive therapy
adjunct to other forms of treat-
ment in alcoholics seeking care.
Specific instructions for fol-
low-up have been given for the
prophylaxis of liver effects. The
transaminases, serum GT and
bilirubin should be assessed be-
fore the introduction of pharma-
ceutical therapy and at 2-week
intervals for the following two
months, followed by the moni-
toring of liver values at 3–6-week
intervals.
Since proof of benefit is avail-
able only from supervised use in
conjunction with other support-
ive measures, and because the ad-
verse effects may be life threaten-
ing, restrictions suggested for the
use of disulfiram should be taken
literally. Adverse liver effects
ought to be actively suspected
and liver values should be
checked.
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Own observation of an adverse reaction
Disulfiram and liver effects
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Use of biological antirheumatic drugs in Finland
in 2005
The biological antirheumatic
agents constitute the most recent
advances in the treatment of
rheumatoid arthritis and other
rheumatic diseases. Biological an-
tirheumatic agents are used in
the treatment of patients who
have not responded to treatment
with conventional antirheumatic
agents. Due to the high costs and
potential of severe adverse ef-
fects, however, the use of biologi-
cal agents has thus far been limit-
ed to relatively few patients.
Biological antirheumatic
agents are protein macromole-
cules produced in cell cultures
and intended for the treatment of
rheumatic diseases. The biologi-
cal agents can delay or even ar-
rest the slow progression of carti-
lage destruction and eventual
joint damage typical of rheuma-
toid joint inflammation. They
can also alleviate symptoms in
such rheumatic diseases which do
not respond to conventional dis-
ease-modifying antirheumatic
drugs. 
Four biological antirheumatic
agents were on the Finnish mar-
ket in 2005. Of these agents, in-
fliximab is not included in the
drug refund system, because it is
used in the form of an infusion
administered to a patient in hos-
pital, whereas etanercept, adali-
mumab and anakinra are given
to the patient in the form of in-
jections. The latter belong to the
group of drugs with limited basic
reimbursability, since they are
very costly and the extensive
therapy is targeted to patients
most likely to benefit from them.
Even though the use of biological
antirheumatic agents has so far
been limited to a few thousands
of patients, in  2005 the costs of
the reimbursed biological an-
tirheumatic agents already
amounted to over 70% of the to-
tal antirheumatic drug costs re-
funded by the Social Insurance
Institution (SII) (1). 
This study investigated the
costs and consumption of biolog-
ical antirheumatic medicinal
products in 2005 by using the re-
fund entitlement database and
the drug purchase records of the
SII. From the records of the SII a
90% sample was taken of the in-
dividuals who had a valid entitle-
ment to a restricted basic reim-
bursement for their biological an-
tirheumatic agents for the entire
year. The requested data did not
include information on the dis-
ease diagnosis or severity. The
subject material consisted of
1,417 individuals, i.e. 71% of
those who had received a refund
for the cost of their biological
antirheumatic agents in 2005.
The material covered 71% of the
total out-patient consumption of
etanercept and adalimumab, and
77% of that of anakinra. 
Results
The vast majority (84%) of the
users of reimbursed biological
antirheumatic agents were 15 to
64 years of age. The median age
of men was 47 years and of
women 49 years. The proportion
of retired people among the 15
to 64-year-olds was 38%, which
reflects the degree of severity of
the disease, as the corresponding
proportion in the general popula-
tion was 13%. 
Etanercept was purchased by
889 of the subjects (63%), adali-
mumab by 627 (44%) and
anakinra by 45 (3%). The major-
ity (1,275, i.e. 90%) had used
only one reimbursed biological
antirheumatic agent during the
year, whereas 140 individuals
(10%) had used two and only
two individuals had used three.
Of those who had used only one
agent, 755 (59%) had used etan-
ercept, 497 (39%) adalimumab
and 23 anakinra (2%). The total
consumption of reimbursed bio-
logical antirheumatics was on av-
erage 297 DDD (median 328
DDD) per person. The consump-
tion among men was on average
300 DDD and women 295 DDD.
The average consumption of
etanercept per person per year
was 267 DDD, adalimumab 279
DDD and anakinra 186 DDD.
The difference between the sexes
was statistically significant only
in the consumption of etanercept,
which was an average of 18
DDD higher in men compared
with women. The average annual
consumption of etanercept per
child among the under 15-year-
olds was 248 DDD (n=77) and
of adalimumab 243 DDD
(n=16). 
Among the subjects, 70% had
also used some conventional dis-
ease-modifying antirheumatic
drug, and 59% had used a sys-
temic glucocorticoid; 45% had
used drugs from both categories
mentioned above, 15% from nei-
ther of them. Systemic glucocor-
ticoids had been used by 40% of
Anna Koski-Pirilä
PhD, Senior Researcher
Planning for Pharmaceutical Policies
National Agency for Medicines
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the under 25-year-olds, 57% of
the 25 to 54-year-olds and 71%
of 55-year-olds and over. Three
quarters had also used analgesics
with basic refund entitlement.
The most common analgesics
were non-steroidal anti-inflam-
matory analgesics (M01A), used
by 71% of the subjects. The
most common of those, ibupro-
fen, had been used by one in
four subjects. 
The annual cost of reim-
bursed biological antirheumatic
drugs was on average EUR
15,800 per year (median EUR
16,900). The average annual cost
of etanercept was EUR 14,300
(median EUR 15,300), of adali-
mumab EUR 15,000 (median
EUR 16,300) and of anakinra
EUR 6,800 (median EUR 6,100).
The refunds paid out by the SII
on average covered 96% of the
costs. The average cost of the
conventional antirheumatics was
EUR 321, and the total costs of
antirheumatics were on average
EUR 16,100. 
Discussion
The clinical response to biologi-
cal antirheumatics is rapid, often
occurring within a couple of
weeks from the introduction of
the treatment. In accordance
with the Finnish Current Care
Guidelines (2), the response to a
biological antirheumatic drug
should be assessed after three
months of treatment by using the
ACR50 criteria set by the Ameri-
can College of Rheumatology. If
no response is obtained, therapy
should be changed. As a rule, bi-
ological antirheumatics are used
as courses of treatment, i.e. until
the rheumatic disease is alleviat-
ed. States of remission are com-
monplace in rheumatic diseases,
and the situation may in fact be
controlled for a longer period of
time, but continuous drug treat-
ment is typically required to
maintain remission.
During the year of survey,
140 subjects used more than one
biological antirheumatic agent,
which is likely to have been an
indication of a change of the pre-
scribed drug. Replacing one bio-
logical medicinal product with
another may be due to poor or
impaired efficacy of the first
drug or to the adverse reactions
it had caused. Adverse effects
caused by biological medicinal
products include allergic reac-
tions and exposure of the patient
to infections. Symptom-free tu-
berculosis in particular may be-
come activated during immuno-
suppressive treatment (2).
In accordance with the
Finnish Current Care Guidelines
for rheumatoid arthritis (2), bio-
logical antirheumatic therapies
should mainly be given in combi-
nation with methotrexate. In
practice this was adhered to in
less than half the survey subjects.
However, methotrexate is not ap-
propriate for all patients, and the
study included also patients with
other rheumatic diseases than
rheumatoid arthritis. 
A systemic glucocorticoid was
combined with biological prod-
ucts in children less often than in
adults, which was probably due
to the possibility that a systemic
glucocorticoid may slow down
growth in the children. Overall,
the use of systemic glucocorti-
coids has been found to be more
common in those who have suf-
fered from rheumatoid arthritis
for a longer period of time (3). 
Active treatment with biologi-
cal antirheumatics is very expen-
sive – a three-month course of
treatment costs about EUR 5,000
– but at its best also very effec-
tive. In a recently published
meta-analysis (4) adalimumab,
etanercept and infliximab were
found to be effective an-
tirheumatics in patients in who
had not satisfactorily responded
to conventional treatment. Etan-
ercept was shown to be the most
cost-effective (4). A recent
Finnish report (5) on overall
costs of rheumatoid arthritis esti-
mated that the majority of the
costs incurred by society consist-
ed of indirect costs in the form
of sickness leaves, disability pen-
sions and lost productivity. Ac-
cording to the reported estimates,
the indirect costs would be even
higher than at present without
the development during the past
two decades of such treatment
methods which inhibit and delay
the progression of rheumatoid
arthritis. The industrial engineer-
ing study was not yet able to as-
sess the effect of biological an-
tirheumatic drugs, but once they
have become common enough, a
similar survey is recommended to
balance the increasing costs of
antirheumatic agents against the
cost savings to society.
Biosimilars?
In recent years, substantial sav-
ings have been achieved in drug
costs with the aid of generic
drugs, to which abbreviated mar-
keting authorisation procedures
are applicable. Due to the com-
plexity of biological drugs, how-
ever, the generic approach is not
adequate for the regulatory ap-
proval of the so called biosimi-
lars (Similar Biological Medicinal
Products). A phenomenon similar
to the cost reduction of small-
molecule drugs is therefore not
to be expected with the biologi-
cal antirheumatic agents within
the near future. Increasing com-
petition and the development of
production technologies can nev-
ertheless be expected to lead to
improved cost efficiency and,
eventually, to reduced prices for
biological antirheumatic agents.
Literature: see page 48.
